AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB. AstraZeneca Pharmaceuticals AB holds 75% of the company's shareholding.
The company operates as a science-led biopharmaceutical enterprise with a strong focus on innovation and bringing advanced therapeutic solutions to Indian patients. AstraZeneca Pharma deals in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology, and respiratory. It has a workforce of 1400 people across the country. AstraZeneca has established a Research & Development facility in Bangalore equipped with a team of 90 employees consisting of scientific experts in the field of regulatory science, clinical science, and patient safety. Its production unit is located in the city of Bengaluru.
The Company operates through the Healthcare segment. The Company is engaged in the business of manufacturing, distribution, and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The company has built a comprehensive portfolio across multiple therapeutic areas with established brand presence in the Indian pharmaceutical market.
It manufactures and sells:
- Cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names.
- Oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names.
- Rare diseases medicines under the Koselugo brand name.
- Respiratory medicines under the Symbicort and Fasenra brand names.
- The company also offers medicines for diabetes and immunology diseases.
Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company's DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
AstraZeneca Pharma India has a Market Cap of ₹21,883 Crore as of the latest available data. The company is almost debt-free. The company has shown strong performance in recent years, with Astrazeneca Pharma India Ltd share price moved up by 59.34% on BSE in the last 12 months and Astrazeneca Pharma India Ltd share price moved up by 273.86% on BSE over the last 3 years.
#### Full Year FY25 Performance
Sales rose 32.48% to ₹1,716.29 Crore in the year ended March 2025, as against ₹1,295.53 Crore during the previous year ended March 2024. Dr. Sanjeev Panchal, country president & managing director of the company, said, "Our company delivered strong growth in Financial Year 2024-25 by launching innovative medicines in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the INR 1,700 crore mark ($200 million)."
However, for the full year, net profit declined 28.34% to ₹115.74 Crore in the year ended March 2025, as against ₹161.51 Crore during the previous year ended March 2024. The board recommended a dividend of ₹32 per equity share for FY25.
#### Quarterly Performance Q4 FY25
Sales rose 25.39% to ₹480.48 Crore in the quarter ended March 2025, as against ₹383.20 Crore during the previous quarter ended March 2024. Net profit of Astrazeneca Pharma India rose 47.54% to ₹58.25 Crore in the quarter ended March 2025, as against ₹39.48 Crore during the previous quarter ended March 2024.
#### Q1 FY25 Performance
AstraZeneca Pharma India Limited, a science-led biopharmaceutical company, achieved a 31% increase in revenue in Q1 FY25 compared to the same period last year to reach ₹387.5 Crore. Profit before exceptional item and tax is ₹42.4 Crore (11% of the total income), reflecting the company's efforts on driving profitable growth.
Bhavana Agrawal, Chief Financial Officer & Director, said: "Our Growth Through Innovation strategy is helping us achieve a robust growth in the country. Our Oncology business last quarter grew by 67%, Biopharmaceutical business grew by 10%, furthering efforts to deliver the next generation of therapeutics in our portfolio and pipeline, and our rare disease business is consistently increasing its focus to help more patients with NF1."
The company has been actively expanding its product portfolio with new approvals and launches. Since 2023, the Company has delivered 12 approvals across its portfolio - Oncology, Biopharmaceutical, Rare Disease. The Company completed 45 years in the country on July 11, 2024, and concluded its 45th Annual General Meeting on August 8, 2024.
AstraZeneca Pharma India received an independent ESG score of 64.9 (Grade B) for FY 2023-24. The company has received several awards including Diversity and Inclusion Award 2024 at the 57th OPPI Annual Day. Awarded 'Silver' for Best Employer for Women in Small Category at the ASSOCHAM 5th Diversity & Inclusion Excellence Awards & Conclave – 2024.
Promoter holding in Astrazeneca Pharma India Ltd has remained stable at 75.00% as of March 2025 (unchanged from June 2024). As of last reported quarter for AstraZeneca Pharma India Ltd., Promoter held 75%, the FII held 2.9%, DII held 5.1%, and the public held 17% of the total shares.
AstraZeneca Pharma India continues to strengthen its position as a leading biopharmaceutical company in India, driven by its focus on innovation, strong product portfolio across critical therapeutic areas, and commitment to bringing advanced healthcare solutions to Indian patients. The company's strategic focus on oncology, cardiovascular, respiratory, and rare diseases positions it well for sustained growth in the evolving Indian pharmaceutical market.
